8 February 2012 Monitoring early tumor response to drug therapy with diffuse optical tomography
Author Affiliations +
J. of Biomedical Optics, 17(1), 016014 (2012). doi:10.1117/1.JBO.17.1.016014
Although anti-angiogenic agents have shown promise as cancer therapeutics, their efficacy varies between tumor types and individual patients. Providing patient-specific metrics through rapid noninvasive imaging can help tailor drug treatment by optimizing dosages, timing of drug cycles, and duration of therapy-thereby reducing toxicity and cost and improving patient outcome. Diffuse optical tomography (DOT) is a noninvasive three-dimensional imaging modality that has been shown to capture physiologic changes in tumors through visualization of oxygenated, deoxygenated, and total hemoglobin concentrations, using non-ionizing radiation with near-infrared light. We employed a small animal model to ascertain if tumor response to bevacizumab (BV), an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF), could be detected at early time points using DOT. We detected a significant decrease in total hemoglobin levels as soon as one day after BV treatment in responder xenograft tumors (SK-NEP-1), but not in SK-NEP-1 control tumors or in non-responder control or BV-treated NGP tumors. These results are confirmed by magnetic resonance imaging T2 relaxometry and lectin perfusion studies. Noninvasive DOT imaging may allow for earlier and more effective control of anti-angiogenic therapy.
© 2012 Society of Photo-Optical Instrumentation Engineers (SPIE)
Molly L. Flexman, Fotios Vlachos, Hyun-Keol Kim, Andreas H. Hielscher, Shashank R. Sirsi, Mark A. Borden, Jianzhong Huang, Tessa B. Johung, Jeffrey W. Gander, Ari R. Reichstein, Darrell J. Yamashiro, Jessica J. Kandel, Sonia L. Hernandez, Brooke S. Lampl, Antai Wang, "Monitoring early tumor response to drug therapy with diffuse optical tomography," Journal of Biomedical Optics 17(1), 016014 (8 February 2012). https://doi.org/10.1117/1.JBO.17.1.016014

Back to Top